Azacitidine Active Not Recruiting Phase 3 Trials for Acute Myeloid Leukemia (AML) / Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02752035A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy